drugset / Trial / NCT00084266

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00084266

Phase 4 Completed 1225 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

Timeline

Start
2004-10
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Linezolid Other / unclassified 600 mg Intravenous
Comparator Vancomycin Other / unclassified 15 mg/kg Intravenous